secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nuvation Bio Inc. (NUVB)
CIK:        0001811063
Form:       8-K
Filed at:   2025-08-07T23:59:59+00:00
Accession:  0001193125-25-174954
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nuvation Bio Q2 net loss $59M; IBTROZI launch with 70 patients in 7 weeks
-------------------------------------------------------------------------

- FDA approved IBTROZI (taletrectinib) for ROS1+ NSCLC on June 11; 70 patients started by July 31.
- Cash, equivalents and marketable securities $607.7M; received $200M non-dilutive financing from Sagard.
- Product revenue net $1.2M from IBTROZI for 13 days of sales; collaboration revenue $3.6M (up from $1.4M).
- Net loss $59M ($0.17/sh) vs $462.5M ($1.89) in prior year which included AnHeart acquisition cost.
- NCCN guidelines added taletrectinib as preferred agent across lines of therapy for ROS1+ NSCLC.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1811063/000119312525174954/0001193125-25-174954-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1811063/000119312525174954/d909051d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-174954

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer